Plain-English translation of NCT04741997 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether encorafenib and binimetinib—two targeted drugs that work together against a specific melanoma mutation—can help prevent advanced melanoma from returning when given before surgery and then continued based on how well the cancer responds. Participants will take these medications for 24 weeks, then have surgery to remove the melanoma. After surgery, some participants will continue the medication while others will be watched closely without additional treatment, depending on how much cancer was eliminated by the initial drug therapy.
Advanced melanoma can be hard to treat and often comes back even after surgery. Doctors want to know if giving this medication before surgery—to shrink the cancer—and then deciding on additional treatment based on how well it worked can help keep the cancer from returning and improve survival.
You likely qualify if…
You likely don't qualify if…
You will take the combination medication by mouth for 24 weeks. During this time, you will have regular clinic visits and imaging scans to see how the cancer is responding. After 24 weeks, you will have surgery to remove the melanoma tumor. Depending on how much cancer was killed by the medication before surgery, you may either continue taking the medication for another 24 weeks or simply be monitored closely with imaging scans every 3 to 6 months for at least 2 years.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Pfizer
Enrollment target
~50 participants
Started
May 2021
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Arnay Marshall
Moffitt Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.